A poly(ascorbyl acrylate)-containing nanoplatform with anticancer activity and the sequential combination therapy with its loaded paclitaxel

2016 ◽  
Vol 4 (40) ◽  
pp. 6588-6596 ◽  
Author(s):  
Yufeng Song ◽  
Yanqi Xie ◽  
Junjiao Yang ◽  
Ruiqiong Li ◽  
Xu Jin ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Anticancer Activity ◽  
Therapeutic Agents ◽  
Tumor Inhibition ◽  
Sequential Combination

The complex nanocarriers combined with the loaded therapeutic agents to achieve synergistic tumor inhibition.

Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma

2020 ◽  
Vol 26 (36) ◽  
pp. 4675-4684 ◽  
Author(s):  
Shabierjiang Jiapaer ◽  
Takuya Furuta ◽  
Yu Dong ◽  
Tomohiro Kitabayashi ◽  
Hemragul Sabit ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Screening ◽  
Therapeutic Agent ◽  
Gelatin Zymography ◽  
Therapeutic Agents ◽  
Drug Candidate ◽  
Potential Therapeutic Agent ◽  
Sphere Formation ◽  
Improve Patient

Background: Glioblastomas (GBMs) are aggressive malignant brain tumors. Although chemotherapy with temozolomide (TMZ) can extend patient survival, most patients eventually demonstrate resistance. Therefore, novel therapeutic agents that overcome TMZ chemoresistance are required to improve patient outcomes. Purpose: Drug screening is an efficient method to find new therapeutic agents from existing drugs. In this study, we explored a novel anti-glioma agent by drug screening and analyzed its function with respect to GBM treatment for future clinical applications. Methods: Drug libraries containing 1,301 diverse chemical compounds were screened against two glioma stem cell (GSC) lines for drug candidate selection. The effect of selected agents on GSCs and glioma was estimated through viability, proliferation, sphere formation, and invasion assays. Combination therapy was performed to assess its ability to enhance TMZ cytotoxicity against GBM. To clarify the mechanism of action, we performed methylation-specific polymerase chain reaction, gelatin zymography, and western blot analysis. Results: The acyl-CoA synthetase inhibitor 2-fluoropalmitic acid (2-FPA) was selected as a candidate anti-glioma agent. 2-FPA suppressed the viability and stem-like phenotype of GSCs. It also inhibited proliferation and invasion of glioma cell lines. Combination therapy of 2-FPA with TMZ synergistically enhanced the efficacy of TMZ. 2-FPA suppressed the expression of phosphor-ERK, CD133, and SOX-2; reduced MMP-2 activity; and increased methylation of the MGMT promoter. Conclusion: 2-FPA was identified as a potential therapeutic agent against GBM. To extend these findings, physiological studies are required to examine the efficacy of 2-FPA against GBM in vivo.

scholarly journals Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium

2021 ◽  
Author(s):  
Hiromitsu Noguchi ◽  
Masahide Kubo ◽  
Kayo Kashiwada‐Nakamura ◽  
Katsunari Makino ◽  
Jun Aoi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Tinea Unguium ◽  
Sequential Combination ◽  
Oral Terbinafine

scholarly journals Bile Acid Conjugates with Anticancer Activity: Most Recent Research

Molecules ◽  
2020 ◽  
Vol 26 (1) ◽  
pp. 25
Author(s):  
Maria Luisa Navacchia ◽  
Elena Marchesi ◽  
Daniela Perrone
Keyword(s):  
Bile Acid ◽  
Cancer Therapy ◽  
Anticancer Activity ◽  
Bile Acids ◽  
Treatment Modality ◽  
Biological Properties ◽  
Therapeutic Agents ◽  
Bioactive Molecules ◽  
Hybrid Functional ◽  
Hybrid Molecules

The advantages of a treatment modality that combines two or more therapeutic agents in cancer therapy encourages the study of hybrid functional compounds for pharmacological applications. In light of this, we reviewed recent works on hybrid molecules based on bile acids. Due to their biological properties, as well as their different chemical/biochemical reactive moieties, bile acids can be considered very interesting starting molecules for conjugation with natural or synthetic bioactive molecules.

scholarly journals Developing Picornaviruses for Cancer Therapy

Cancers ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 685 ◽  
Author(s):  
Cormac McCarthy ◽  
Nadishka Jayawardena ◽  
Laura N. Burga ◽  
Mihnea Bostina
Keyword(s):  
Cancer Therapy ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Rna Viruses ◽  
Therapeutic Agents ◽  
Oncolytic Viruses ◽  
Wide Range ◽  
Positive Sense

Oncolytic viruses (OVs) form a group of novel anticancer therapeutic agents which selectively infect and lyse cancer cells. Members of several viral families, including Picornaviridae, have been shown to have anticancer activity. Picornaviruses are small icosahedral non-enveloped, positive-sense, single-stranded RNA viruses infecting a wide range of hosts. They possess several advantages for development for cancer therapy: Their genomes do not integrate into host chromosomes, do not encode oncogenes, and are easily manipulated as cDNA. This review focuses on the picornaviruses investigated for anticancer potential and the mechanisms that underpin this specificity.

scholarly journals Sequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome

2009 ◽  
Vol 3 (1) ◽  
pp. 18-21 ◽  
Author(s):  
C. E. Huber ◽  
A. G. Judex ◽  
J. Freyschmidt ◽  
S. Feuerbach ◽  
J. Scholmerich ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Sapho Syndrome ◽  
Sustained Remission ◽  
Sequential Combination

scholarly journals Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

2020 ◽  
Vol 10 (3) ◽  
pp. 204589402094212
Author(s):  
Hossein-Ardeschir Ghofrani ◽  
Ekkehard Grünig ◽  
Pavel Jansa ◽  
David Langleben ◽  
Stephan Rosenkranz ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Receptor Antagonist ◽  
Endothelin Receptor Antagonist ◽  
Walking Distance ◽  
Endothelin Receptor ◽  
Pretreated Patients ◽  
Sequential Combination ◽  
Pulmonary Arterial

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg–maximum ( N = 131 pretreated patients) and placebo ( N = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: –8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies.

scholarly journals The role of combination therapy in managing pulmonary arterial hypertension

2014 ◽  
Vol 23 (134) ◽  
pp. 469-475 ◽  
Author(s):  
Hossein-Ardeschir Ghofrani ◽  
Marc Humbert
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Treatment Algorithm ◽  
Supporting Evidence ◽  
Potential Clinical Benefit ◽  
Treatment Naïve ◽  
Sequential Combination ◽  
Pulmonary Arterial ◽  
Randomised Controlled

Pulmonary arterial hypertension (PAH) is a complex, progressive disease with several pathobiological mechanisms, including the endothelin, nitric oxide and prostacyclin pathways. Current treatments for PAH target one of these pathways and, in more severe cases or instances of disease worsening, may be combined with a view to target multiple pathways in parallel. Treatment combination is performed sequentially (as an intensification from initial monotherapy) or upfront (use of two or more therapies in treatment-naïve patients). Whilst combination therapy has been historically considered to be an option for the treatment of PAH, supporting evidence was typically limited to expert opinion, clinical experience and registry data.Data from randomised controlled trials on sequential combination therapy in particular has grown in recent years, resulting in a change in the level of recommendations in the latest update to the PAH treatment algorithm. However, short-term trials have shown inconsistent results, and have not been powered to assess morbidity/mortality outcomes. More recent data from long-term trials suggest a potential clinical benefit associated with sequential combination therapy.In this review we will introduce the concept of combination therapy, consider the latest evidence for both sequential and upfront combination therapy, and discuss additional considerations when initiating combination therapy in clinical practice.

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

2010 ◽  
Vol 27 (1) ◽  
pp. 189-195 ◽  
Author(s):  
Bhavik J. Pandya ◽  
Morgan Bron ◽  
Therese McCall ◽  
Andrew P. Yu ◽  
Kristina S. Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Sequential Combination
Sign in / Sign up

Export Citation Format

Share Document